Novel Bio
New York, United States· Est.
Domestic CDMO delivering fast, cost‑effective plasmid DNA for gene‑therapy and mRNA programs.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Domestic CDMO delivering fast, cost‑effective plasmid DNA for gene‑therapy and mRNA programs.
Gene TherapyVaccinesRNA TherapeuticsCell & Gene Therapy
Technology Platform
Optimized E. coli fermentation and proprietary purification workflows delivering high‑purity, supercoiled plasmid DNA with rapid turnaround and tiered QC packages.
Opportunities
Growing demand for domestic, cost‑effective plasmid DNA in gene‑therapy and mRNA vaccine pipelines; potential expansion into viral vector and mRNA manufacturing.
Risk Factors
Scaling GMP capacity while maintaining quality; competition from larger CDMOs; regulatory scrutiny of plasmid production processes.
Competitive Landscape
Competes with established CDMOs such as Aldevron and Thermo Fisher, differentiating through domestic production, lower pricing, and rapid, tiered QC services.